US 12,304,909 B2
Compounds and their use in therapy
Edward William Tate, London (GB); and Andrew Simon Bell, London (GB)
Assigned to IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB)
Appl. No. 17/414,712
Filed by IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB)
PCT Filed Dec. 19, 2019, PCT No. PCT/GB2019/053613
§ 371(c)(1), (2) Date Jun. 16, 2021,
PCT Pub. No. WO2020/128473, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 1820659 (GB), filed on Dec. 19, 2018.
Prior Publication US 2022/0064158 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 10 Claims
 
1. A compound which is: 4-(2-{2-[3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl]-5-chlorophenoxy}ethyl)-N,N,1,5-tetramethyl-1H-pyrazole-3-carboxamide:

OG Complex Work Unit Chemistry
or
4-(2-{2-[3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl]-5-chlorophenoxy}ethyl)-N,N,1,5-tetramethyl-1H-pyrazole-3-carboxamide:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable amide, carbamate or salt of any one thereof, including a salt of said amide or carbamate.